| Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Clinical decision-making and treatment of myelodysplastic syndromes |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Elderly Patients With Aplastic Anemia: Treatment Patterns and Outcomes in the Real World |
|
American Journal of Hematology |
Aplastic Anemia |
| Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Myelodysplastic Syndromes: 2021 update on Diagnosis, Risk-stratification and Management |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
